E-ISSN 2534-9821
 

Mini Review 


Neutrophil to lymphocyte ratio in immunotherapy for malignancies

Bassim Kobrossy.

Abstract
In the quest for a simple and effective biomarker for PD-1 antibody efficacy many candidates have emerged. The simplest one is the ratio between neutrophils and lymphocytes (NLR) in peripheral blood. Since 2012 the emergence of checkpoint inhibitor therapy has introduced a new paradigm in cancer therapy, adding a powerful tool in the oncology treatment armamentarium. The progress achieved in clinical trials have revealed efficacy in different tumor types and with different immunotherapy combinations. However optimal duration of therapy, optimal dose, optimal schedule, are for the most part unknown. In this review we will discuss the utility of information obtained from the peripheral blood CBC as a contributor to solving this question.

Key words: pd1, checkpoint inhibitors, neutrophil to lymphocyte ratio


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Bassim Kobrossy
on Google
on Google Scholar
Article Statistics
 Viewed: 348
Downloaded: 44


How to Cite this Article
Pubmed Style

Bassim Kobrossy. Neutrophil to lymphocyte ratio in immunotherapy for malignancies. Int J Med Rev Case Rep. 2020; 4(1): 11-13. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology


Web Style

Bassim Kobrossy. Neutrophil to lymphocyte ratio in immunotherapy for malignancies. http://www.mdpub.net/?mno=82035 [Access: April 03, 2020]. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology


AMA (American Medical Association) Style

Bassim Kobrossy. Neutrophil to lymphocyte ratio in immunotherapy for malignancies. Int J Med Rev Case Rep. 2020; 4(1): 11-13. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology



Vancouver/ICMJE Style

Bassim Kobrossy. Neutrophil to lymphocyte ratio in immunotherapy for malignancies. Int J Med Rev Case Rep. (2020), [cited April 03, 2020]; 4(1): 11-13. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology



Harvard Style

Bassim Kobrossy (2020) Neutrophil to lymphocyte ratio in immunotherapy for malignancies. Int J Med Rev Case Rep, 4 (1), 11-13. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology



Turabian Style

Bassim Kobrossy. 2020. Neutrophil to lymphocyte ratio in immunotherapy for malignancies. International Journal of Medical Reviews and Case Reports, 4 (1), 11-13. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology



Chicago Style

Bassim Kobrossy. "Neutrophil to lymphocyte ratio in immunotherapy for malignancies." International Journal of Medical Reviews and Case Reports 4 (2020), 11-13. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology



MLA (The Modern Language Association) Style

Bassim Kobrossy. "Neutrophil to lymphocyte ratio in immunotherapy for malignancies." International Journal of Medical Reviews and Case Reports 4.1 (2020), 11-13. Print. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology



APA (American Psychological Association) Style

Bassim Kobrossy (2020) Neutrophil to lymphocyte ratio in immunotherapy for malignancies. International Journal of Medical Reviews and Case Reports, 4 (1), 11-13. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology